title: Rheumatoid arthritis: International disparities in access to anti-TNF therapy.
abstract: The establishment of new benchmarks for treatment outcomes promises to drive great advances in rheumatoid arthritis therapy, but data on ‘real life’ experience with biologic therapy demonstrate that geographic location influences the stage of disease at which these agents are initiated.
authors: NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Academic Section of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. p.emery@leeds.ac.uk
authors: Paul
authors: P
authors: Emery
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003710:Demography; D005843:Geography; D014943:Global Health; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha